Continuous glucose monitoring threshold alerts improve time in range and reduce time above range for hospitalized adults with diabetes.

Compared with standard care alone, a hybrid lifestyle intervention did not significantly improve weight loss in adults with obesity.

The prevalence of neurodiversity is increased among individuals diagnosed with type 2 diabetes (T2D) early in life.

PACE is the first phase 3 randomized trial directly comparing radical prostatectomy with SBRT in men with low- to intermediate-risk prostate cancer.

For postmenopausal women with early-stage HR+ breast cancer, long-term adherence to AIs is linked to greater cardiometabolic risks than tamoxifen.

Continuous glucose monitoring yields modest reductions in hemoglobin A1c levels in adults with type 2 diabetes compared with standard care.

Therapy with GLP-1 RAs reduces the frequency of apnea and hypopnea events in obesity, serving as an effective adjunct to ...

Tirzepatide therapy reduces the risk for major adverse cardiovascular events in patients with type 2 diabetes and established CVD.

Elevated maternal body mass index and excessive weight gain during pregnancy increase the risk of early-onset CVD in offspring.

The FDA has approved Bravnetsa (lutetium Lu 177 dotatate) via the ANDA pathway as a bioequivalent treatment option for SSTR-positive GEP-NETs.

The FDA has approved Degevma (denosumab-adet), a new biosimilar to Xgeva, to prevent skeletal-related events in patients with bone metastases.

Few women initiate systemic hormone therapy for menopausal symptoms, and the majority of patients who do discontinue treatment within the first year.